New Hikma CEO Eyes M&A, Upbeat Despite Generic Advair Woes
Executive Summary
Sigurdur Olafsson is impressed with the balance sheet he has inherited at Hikma and said he is looking forward to both organic and inorganic growth.
You may also be interested in...
Stock Scan March 2018: Trading Down, Pairing Up
Merger and acquisition, or collaboration at least, was in the air during March as big pharma took stock of its opportunities in the midst of a disturbed market.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.